Share-based Payment Arrangement, Noncash Expense of ANAVEX LIFE SCIENCES CORP. from 30 Sep 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of noncash expense for share-based payment arrangement.
Summary
ANAVEX LIFE SCIENCES CORP. quarterly and annual Share-based Payment Arrangement, Noncash Expense in USD history and change rate from 30 Sep 2010 to 31 Dec 2025.
  • ANAVEX LIFE SCIENCES CORP. Share-based Payment Arrangement, Noncash Expense for the quarter ending 31 Dec 2025 was $1,107,000, a 46% decline year-over-year.
  • ANAVEX LIFE SCIENCES CORP. Share-based Payment Arrangement, Noncash Expense for the twelve months ending 31 Dec 2025 was $10,601,000, a 15% increase year-over-year.
  • ANAVEX LIFE SCIENCES CORP. annual Share-based Payment Arrangement, Noncash Expense for 2025 was $11,549,000, a 22% increase from 2024.
  • ANAVEX LIFE SCIENCES CORP. annual Share-based Payment Arrangement, Noncash Expense for 2024 was $9,438,000, a 42% decline from 2023.
  • ANAVEX LIFE SCIENCES CORP. annual Share-based Payment Arrangement, Noncash Expense for 2023 was $16,370,000, a 11% decline from 2022.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Noncash Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Noncash Expense, Quarterly (USD)
Share-based Payment Arrangement, Noncash Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Noncash Expense, Annual (USD)
Share-based Payment Arrangement, Noncash Expense, YoY Annual Change (%)

ANAVEX LIFE SCIENCES CORP. Quarterly Share-based Payment Arrangement, Noncash Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 $10,601,000 $1,107,000 -$948,000 -46% 01 Oct 2025 31 Dec 2025 10-Q 09 Feb 2026 2026 Q1
Q3 2025 $11,549,000 $3,721,000 +$1,709,000 +85% 01 Jul 2025 30 Sep 2025 10-K 25 Nov 2025 2025 FY
Q2 2025 $9,840,000 $4,324,000 +$1,836,000 +74% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q3
Q1 2025 $8,004,000 $1,449,000 -$1,203,000 -45% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q2
Q4 2024 $9,207,000 $2,055,000 -$231,000 -10% 01 Oct 2024 31 Dec 2024 10-Q 09 Feb 2026 2026 Q1
Q3 2024 $9,438,000 $2,012,000 -$1,175,000 -37% 01 Jul 2024 30 Sep 2024 10-K 25 Nov 2025 2025 FY
Q2 2024 $10,613,000 $2,488,000 -$1,378,000 -36% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q3
Q1 2024 $11,991,000 $2,652,000 -$1,318,000 -33% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q2
Q4 2023 $13,309,000 $2,286,000 -$3,061,000 -57% 01 Oct 2023 31 Dec 2023 10-Q 12 Feb 2025 2025 Q1
Q3 2023 $16,370,000 $3,187,000 -$2,855,159 -47% 01 Jul 2023 30 Sep 2023 10-K 25 Nov 2025 2025 FY
Q2 2023 $19,225,159 $3,866,000 -$122,614 -3.1% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q3
Q1 2023 $19,347,773 $3,970,000 -$469,456 -11% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q2
Q4 2022 $19,817,229 $5,347,000 +$1,438,229 +37% 01 Oct 2022 31 Dec 2022 10-Q 07 Feb 2024 2024 Q1
Q3 2022 $18,379,000 $6,042,159 +$2,890,554 +92% 01 Jul 2022 30 Sep 2022 10-K 27 Nov 2023 2023 FY
Q2 2022 $15,488,446 $3,988,614 +$1,694,689 +74% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2022 2022 Q3
Q1 2022 $13,793,757 $4,439,456 +$2,593,300 +140% 01 Jan 2022 31 Mar 2022 10-Q 10 May 2022 2022 Q2
Q4 2021 $11,200,457 $3,908,771 +$2,969,457 +316% 01 Oct 2021 31 Dec 2021 10-Q 07 Feb 2023 2023 Q1
Q3 2021 $8,231,000 $3,151,605 +$2,491,005 +377% 01 Jul 2021 30 Sep 2021 10-K 27 Nov 2023 2023 FY
Q2 2021 $5,739,995 $2,293,925 +$1,042,796 +83% 01 Apr 2021 30 Jun 2021 10-Q 09 Aug 2022 2022 Q3
Q1 2021 $4,697,199 $1,846,156 +$145,403 +8.5% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q2
Q4 2020 $4,551,796 $939,314 -$325,110 -26% 01 Oct 2020 31 Dec 2020 10-Q 09 Feb 2022 2022 Q1
Q3 2020 $4,876,906 $660,600 01 Jul 2020 30 Sep 2020 10-K 28 Nov 2022 2022 FY
Q2 2020 $1,251,129 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q3
Q1 2020 $1,700,753 -$192,399 -10% 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q2
Q4 2019 $1,264,424 -$802,563 -39% 01 Oct 2019 31 Dec 2019 10-Q 16 Feb 2021 2021 Q1
Q1 2019 $1,893,152 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q2
Q4 2018 $2,066,987 +$945,002 +84% 01 Oct 2018 31 Dec 2018 10-Q 06 Feb 2020 2020 Q1
Q4 2017 $1,121,985 +$232,718 +26% 01 Oct 2017 31 Dec 2017 10-Q 07 Feb 2019 2019 Q1
Q4 2016 $889,267 +$63,247 +7.7% 01 Oct 2016 31 Dec 2016 10-Q 07 Feb 2018 2017 Q1
Q4 2015 $826,020 +$810,658 +5277% 01 Oct 2015 31 Dec 2015 10-Q 07 Feb 2017 2017 Q1
Q4 2014 $15,362 +$15,362 01 Oct 2014 31 Dec 2014 10-Q 08 Feb 2016 2016 Q1
Q4 2013 $0 $0 01 Oct 2013 31 Dec 2013 10-Q 17 Feb 2015 2015 Q1
Q4 2012 $0 -$123,264 -100% 01 Oct 2012 31 Dec 2012 10-Q 14 Feb 2014 2014 Q1
Q4 2011 $123,264 -$64,486 -34% 01 Oct 2011 31 Dec 2011 10-Q 14 Feb 2013 2013 Q1
Q4 2010 $187,750 01 Oct 2010 31 Dec 2010 10-Q 14 Feb 2012 2012 Q1

ANAVEX LIFE SCIENCES CORP. Annual Share-based Payment Arrangement, Noncash Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2025 $11,549,000 +$2,111,000 +22% 01 Oct 2024 30 Sep 2025 10-K 25 Nov 2025 2025 FY
2024 $9,438,000 -$6,932,000 -42% 01 Oct 2023 30 Sep 2024 10-K 25 Nov 2025 2025 FY
2023 $16,370,000 -$2,009,000 -11% 01 Oct 2022 30 Sep 2023 10-K 25 Nov 2025 2025 FY
2022 $18,379,000 +$10,148,000 +123% 01 Oct 2021 30 Sep 2022 10-K 27 Nov 2023 2023 FY
2021 $8,231,000 +$3,354,094 +69% 01 Oct 2020 30 Sep 2021 10-K 27 Nov 2023 2023 FY
2020 $4,876,906 -$1,553,967 -24% 01 Oct 2019 30 Sep 2020 10-K 28 Nov 2022 2022 FY
2019 $6,430,873 +$913,869 +17% 01 Oct 2018 30 Sep 2019 10-K 28 Dec 2020 2020 FY
2018 $5,517,004 +$1,381,434 +33% 01 Oct 2017 30 Sep 2018 10-K 16 Dec 2019 2019 FY
2017 $4,135,570 -$926,697 -18% 01 Oct 2016 30 Sep 2017 10-K 25 Jan 2019 2018 FY
2016 $5,062,267 +$3,428,288 +210% 01 Oct 2015 30 Sep 2016 10-K 25 Jan 2019 2018 FY
2015 $1,633,979 +$996,054 +156% 01 Oct 2014 30 Sep 2015 10-K 11 Dec 2017 2017 FY
2014 $637,925 -$364,575 -36% 01 Oct 2013 30 Sep 2014 10-K 14 Dec 2016 2016 FY
2013 $1,002,500 +$700,292 +232% 01 Oct 2012 30 Sep 2013 10-K 29 Dec 2014 2014 FY
2012 $302,208 -$970,954 -76% 01 Oct 2011 30 Sep 2012 10-K 30 Dec 2013 2013 FY
2011 $1,273,162 +$503,107 +65% 01 Oct 2010 30 Sep 2011 10-K 31 Dec 2012 2012 FY
2010 $770,055 01 Oct 2009 30 Sep 2010 10-K 22 Dec 2011 2011 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.